• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专业抗原呈递细胞与半专业或非专业抗原呈递细胞在血管化器官同种异体移植排斥反应中作用的比较研究。

Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.

作者信息

Sundstrom J B, Ansari A A

机构信息

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

出版信息

Transpl Immunol. 1995 Dec;3(4):273-89. doi: 10.1016/0966-3274(95)80013-1.

DOI:10.1016/0966-3274(95)80013-1
PMID:8665146
Abstract

The immune systems of transplant recipients are progressively challenged with exposure to the multiple lineages of donor cells that comprise the vascularized organ allograft. Each lineage of such donor tissue constitutively expresses or can be induced to express varying densities of MHC antigens ranging from no expression of MHC to MHC class I only to both MHC class I and class II. In addition, the cell surface expression of a diverse assortment of costimulatory and cell adhesion molecules also varies in density in a tissue specific fashion within the allograft. The MHC class I/II molecules displayed on the donor cells contain within their clefts a constellation of processed protein antigens in the form of peptides derived from intracellular and to some extent extracellular sources. Therefore, the potential for each cell lineage to induce alloactivation and serve as a target for allospecific immune responses is dependent on the diversity and density of peptide-bearing MHC molecules, costimulatory molecules, and cell adhesion molecules. In addition, the T cell receptor repertoire of the recipient also contributes to the magnitude of the allogeneic response. Consequently, the variety of clinical outcomes following organ transplantation even with the institution of potent immunosuppressive (drug) therapies is not surprising, as it appears reasonable for such therapies to influence the allogeneic response against distinct lineages differentially. Our failure to prevent chronic human allograft rejection may therefore be due to our limited appreciation of the full spectrum of alloactivating experiences encountered by host T cells as they interact with donor cells of diverse tissue lineages. Investigations by our laboratory of the immunopathogenesis of chronic cardiac allograft rejection have revealed an intrinsic inability of human cardiac myocytes to process and present antigens, not only for primary but also for secondary alloimmune responses. One obvious explanation for this phenomenon is the fact that cardiac myocytes do not constitutively express MHC class II molecules and express only low levels of class I molecules. However, this immunological unresponsiveness is maintained even after the induction of MHC class II and upregulation of MHC class I on these cells by interferon-gamma (IFN-gamma). Similar results have also been reported for cells of different tissue lineages (e.g. chondrocytes, keratinocytes, neural cells). Until now, cells have been defined as professional or nonprofessional for the purposes of defining their potential for antigen presentation to T cells. Professional antigen presenting cells have been identified as cells that are of haematopoietic origin, that constitutively express MHC class I and class II molecules as well as potent costimulatory molecules, and that are able to induce both primary and secondary immune responses, whereas nonprofessional antigen presenting cells are not bone marrow derived, do not constitutively express MHC class II, but may in some cases initiate primary and secondary immune responses after induction of MHC class II antigen by proinflammatory cytokines (e.g. IFN-gamma). The findings of our laboratory and others suggest that cells of certain lineages be considered in the separate class of 'nonantigen presenting cells'. Indeed, nonprofessional antigen presenting cells can be reclassified into three categories: semiprofessional-, nonprofessional-, or nonantigen presenting cells that are able to present antigen to and activate naive T cells, activated T cells, or no T Cells, respectively. The aim of this review is to identify and (re)examine the antigen presentation characteristics of cells of different tissue lineages in terms of their ability to activate different subsets of T cells. This approach is taken in an attempt to synthesize these concepts into a unified picture of T cell activation in the context of antigen processing and presentation by different cell types.

摘要

移植受者的免疫系统会因接触构成血管化器官同种异体移植物的多种供体细胞谱系而不断受到挑战。这种供体组织的每个谱系都组成性地表达或可被诱导表达不同密度的MHC抗原,范围从无MHC表达到仅表达MHC I类,再到同时表达MHC I类和II类。此外,多种共刺激分子和细胞黏附分子的细胞表面表达在同种异体移植物内也以组织特异性方式呈现密度变化。供体细胞上展示的MHC I/II类分子在其裂隙中包含一系列加工后的蛋白质抗原,这些抗原以源自细胞内以及在一定程度上源自细胞外的肽的形式存在。因此,每个细胞谱系诱导同种激活并作为同种特异性免疫反应靶标的潜力取决于携带肽的MHC分子、共刺激分子和细胞黏附分子的多样性和密度。此外,受者的T细胞受体库也会影响同种异体反应的强度。因此,即使采用强效免疫抑制(药物)疗法,器官移植后的临床结果仍存在差异也就不足为奇了,因为此类疗法似乎会以不同方式影响针对不同谱系的同种异体反应。因此,我们未能预防慢性人类同种异体移植排斥反应可能是由于我们对宿主T细胞与不同组织谱系的供体细胞相互作用时所遇到的全谱同种激活经历了解有限。我们实验室对慢性心脏同种异体移植排斥反应的免疫发病机制进行的研究表明,人类心肌细胞内在地无法处理和呈递抗原,不仅对于初次同种免疫反应如此,对于二次同种免疫反应也是如此。对此现象的一个明显解释是,心肌细胞不组成性表达MHC II类分子,仅表达低水平的I类分子。然而,即使在通过干扰素-γ(IFN-γ)诱导这些细胞上的MHC II类表达并上调MHC I类表达后,这种免疫无反应性仍然存在。对于不同组织谱系的细胞(如软骨细胞、角质形成细胞、神经细胞)也有类似的报道。到目前为止,为了定义细胞向T细胞呈递抗原的潜力,细胞被分为专职或非专职。专职抗原呈递细胞已被确定为造血起源的细胞,它们组成性地表达MHC I类和II类分子以及强效共刺激分子,并且能够诱导初次和二次免疫反应,而非专职抗原呈递细胞并非源自骨髓,不组成性表达MHC II类,但在某些情况下,在促炎细胞因子(如IFN-γ)诱导MHC II类抗原后可能引发初次和二次免疫反应。我们实验室和其他实验室的研究结果表明,某些谱系的细胞应被归入“非抗原呈递细胞”这一单独类别。事实上,非专职抗原呈递细胞可重新分类为三类:分别能够向未活化T细胞、活化T细胞或不向T细胞呈递抗原并激活它们的半专职、非专职或非抗原呈递细胞。本综述的目的是根据不同组织谱系细胞激活不同T细胞亚群的能力,识别并(重新)审视它们的抗原呈递特征。采取这种方法是为了将这些概念综合成一幅在不同细胞类型进行抗原加工和呈递的背景下T细胞激活的统一图景。

相似文献

1
Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.专业抗原呈递细胞与半专业或非专业抗原呈递细胞在血管化器官同种异体移植排斥反应中作用的比较研究。
Transpl Immunol. 1995 Dec;3(4):273-89. doi: 10.1016/0966-3274(95)80013-1.
2
The immunogenic potential of human fetal retinal pigment epithelium and its relation to transplantation.人胎儿视网膜色素上皮的免疫原性潜能及其与移植的关系。
Invest Ophthalmol Vis Sci. 1997 Nov;38(12):2662-71.
3
Immune selection in murine tumors. Ph.d thesis.小鼠肿瘤中的免疫选择。博士论文。
APMIS Suppl. 2003(106):1-46.
4
Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.大鼠自身免疫性心肌炎中抗原呈递细胞的鉴定与特征:骨髓来源的证据以及与致病性T细胞不要求MHC I类相容性。
J Autoimmun. 2000 Nov;15(3):369-79. doi: 10.1006/jaut.2000.0431.
5
Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.树突状细胞类型,即哺乳动物胸腺微环境中的辅助细胞。树突状神经-内分泌-免疫细胞网络中的抗原呈递。
In Vivo. 1997 Jul-Aug;11(4):351-70.
6
[The immune response to kidney allograft. Part I: the role of MHC antigens, antigen-presenting cells, and lymphocytes in alloantigen recognition; two-signal activation of T cells].[对肾移植的免疫反应。第一部分:主要组织相容性复合体(MHC)抗原、抗原呈递细胞和淋巴细胞在同种异体抗原识别中的作用;T细胞的双信号激活]
Postepy Hig Med Dosw (Online). 2007;61:13-20.
7
The influence of MHC and non-MHC genes on the nature of murine cardiac allograft rejection. I. Kinetic analysis of mononuclear cell infiltrate and MHC-class I/class II expression in donor tissue.主要组织相容性复合体(MHC)和非MHC基因对小鼠心脏同种异体移植排斥反应性质的影响。I. 供体组织中单核细胞浸润及MHC I类/II类表达的动力学分析
Transplantation. 1990 Aug;50(2):313-24. doi: 10.1097/00007890-199008000-00028.
8
Activation of alloreactive T cells by allogeneic nonprofessional antigen-presenting cells and interleukin-12 from bystander autologous professional antigen-presenting cells.同种异体非专职抗原呈递细胞以及来自旁观者自体专职抗原呈递细胞的白细胞介素-12激活同种反应性T细胞。
Transplantation. 2000 Apr 27;69(8):1637-44. doi: 10.1097/00007890-200004270-00020.
9
Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.细菌抗原递呈系统:细菌抗原的吞噬加工,用于MHC-I和MHC-II呈递给T细胞。
Behring Inst Mitt. 1997 Feb(98):197-211.
10
Allograft survival following immunization with membrane-bound or soluble peptide MHC class I donor antigens: factors relevant for the induction of rejection by indirect recognition.用膜结合或可溶性肽MHC I类供体抗原免疫后的同种异体移植存活:与间接识别诱导排斥相关的因素。
Transpl Int. 1996;9(1):2-8. doi: 10.1007/BF00336805.

引用本文的文献

1
Emerging approaches for T cell-stimulating platform development.T细胞刺激平台开发的新兴方法。
Cell Syst. 2024 Dec 18;15(12):1198-1208. doi: 10.1016/j.cels.2024.11.007.
2
Immune Cytolytic Activity and Strategies for Therapeutic Treatment.免疫细胞溶解活性与治疗策略。
Int J Mol Sci. 2024 Mar 23;25(7):3624. doi: 10.3390/ijms25073624.
3
Role of B cells as antigen presenting cells.B 细胞作为抗原呈递细胞的作用。
Front Immunol. 2022 Sep 8;13:954936. doi: 10.3389/fimmu.2022.954936. eCollection 2022.
4
Adipose tissue lymphocytes: types and roles.脂肪组织淋巴细胞:类型和作用。
J Physiol Biochem. 2009 Dec;65(4):423-36. doi: 10.1007/BF03185938.
5
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells.角质形成细胞中肿瘤坏死因子相关凋亡诱导配体(TRAIL)的表达介导同种异体T细胞的凋亡性细胞死亡。
Ann Surg Innov Res. 2009 Nov 19;3:13. doi: 10.1186/1750-1164-3-13.
6
An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing.一种用于在重复给予粒细胞-巨噬细胞集落刺激因子(GM-CSF)情况下对外周血树突状细胞进行计数的流式细胞术替代策略。
J Transl Med. 2006 Apr 24;4:18. doi: 10.1186/1479-5876-4-18.
7
Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?老年癌症患者的免疫治疗:非清髓性预处理后的异基因骨髓移植能否提供新的选择?
Cancer Immunol Immunother. 2004 Aug;53(8):659-76. doi: 10.1007/s00262-004-0503-2. Epub 2004 Apr 6.
8
Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.MHC I类依赖性免疫豁免的崩溃与恢复:以人类毛囊为模型进行研究
Am J Pathol. 2004 Feb;164(2):623-34. doi: 10.1016/S0002-9440(10)63151-3.
9
Specific immunotherapy of cancer in elderly patients.老年患者癌症的特异性免疫疗法。
Drugs Aging. 2001;18(9):639-64. doi: 10.2165/00002512-200118090-00002.
10
Prophylaxis of cytomegalovirus disease in high-risk patients.高危患者巨细胞病毒病的预防
Infection. 1997 Sep-Oct;25(5):269-73. doi: 10.1007/BF01720395.